The effect of ABT-702, a novel adenosine kinase inhibitor, on the responses of spinal neurones following carrageenan inflammation and peripheral nerve injury
Open Access
- 1 April 2001
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 132 (7), 1615-1623
- https://doi.org/10.1038/sj.bjp.0703972
Abstract
Adenosine (ADO) receptor activation modulates sensory transmission in the dorsal horn. Little is known about the circumstances underlying release of the purine. The present study was conducted to investigate the effect of a novel and potent non‐nucleoside adenosine kinase (AK) inhibitor, ABT‐702, on the responses of dorsal horn neurones to selected peripheral stimuli. ABT‐702 is orally effective to reduce behavioural signs of nociception in models of acute, inflammatory, and neuropathic pain. Electrophysiological recordings were made from wide dynamic range (WDR) neurones in halothane‐anaesthetized rats. ABT‐702 was given subcutaneously following either carrageenan inflammation or peripheral nerve injury (L5/L6 spinal nerve ligation). Comparisons were made between carrageenan and uninjected control animals, and similarly between spinal nerve ligated (SNL) and sham operated animals. ABT‐702 produced inhibition of the postdischarge, wind‐up and C‐fibre evoked responses in both carrageenan and nerve‐injured animals. Furthermore, the mechanical and thermal evoked responses were similarly reduced in SNL rats. Overall, ABT‐702 produced a significantly greater inhibition of these responses in SNL rats as compared to sham controls. Similarly ABT‐702 tended to produce greater effects after carrageenan inflammation, however this did not reach significance. Protection of endogenous adenosine by ABT‐702 therefore produces a marked inhibition of the noxious evoked neuronal activity in inflamed and neuropathic rats. Our results demonstrate a plasticity in the endogenous adenosine‐mediated inhibitory system following SNL and provide a possible basis for the use of this compound for the treatment of neuropathic and other persistent pain states. British Journal of Pharmacology (2001) 132, 1615–1623; doi:10.1038/sj.bjp.0703972Keywords
This publication has 40 references indexed in Scilit:
- The Safety and Efficacy of Intrathecal Adenosine in Patients with Chronic Neuropathic PainAnesthesia & Analgesia, 1999
- The Safety and Efficacy of Intrathecal Adenosine in Patients with Chronic Neuropathic PainAnesthesia & Analgesia, 1999
- Reduced Anti-Allodynic Effect of the Adenosine A1-Receptor Agonist R-Phenylisopropyladenosine on Repeated Intrathecal Administration and Lack of Cross-Tolerance with Morphine in a Rat Model of Central PainAnesthesia & Analgesia, 1998
- Systemic Adenosine Infusion Alleviates Spontaneous and Stimulus Evoked Pain in Patients with Peripheral Neuropathic PainAnesthesia & Analgesia, 1995
- Systemic adenosine infusion: a new treatment modality to alleviate neuropathic painPain, 1995
- An A1-Selective Adenosine Agonist Abolishes Allodynia Elicited by Vibration and Touch After Intrathecal InjectionAnesthesia & Analgesia, 1995
- Local Antinociceptive and Hyper algesic Effects in the Formalin Test after Peripheral Administration of Adenosine Analogues in MiceBasic & Clinical Pharmacology & Toxicology, 1992
- Effects of Intrathecal Injection of the Adenosine Receptor Agonists R-Phenylisopropyl-Adenosine and N-Ethylcarboxamide-Adenosine on Nociception and Motor Function in the RatAnesthesia & Analgesia, 1990
- Local and remote modifications of nociceptive sensitivity during carrageenin-induced inflammation in the ratPain, 1987
- Ethical guidelines for investigations of experimental pain in conscious animalsPain, 1983